Humanoid robots: Trump-linked startup plans Phantom for military

San Francisco‑based startup Foundation (also referred to in reports as Foundation Future Industries or Foundation Robotics) is developing the Phantom MK‑1 humanoid robot with explicit military and industrial use cases, and has been conducting field tests including the shipment of two prototype units to Ukraine for evaluation. Major outlets report the company holds multimillion‑dollar research contracts with U.S. defense branches.

Founded by Sankaet Pathak with co‑founders including former Marine Mike LeBlanc, Foundation has publicly discussed both industrial and defense applications for Phantom. Reporting by Time and Fox Business indicates the firm has secured a combined figure of research contracts reported around $24 million, while NBC Bay Area’s investigative coverage notes at least $18 million in contract awards in federal procurement records. Time and other outlets also report that Eric Trump is an investor and serves as the company’s chief strategy adviser.

The commercial and market implications are immediate: defense procurement officials, private investors and robotics suppliers are reassessing production pipelines, component supply and certification timelines. Foundation has signaled aggressive scaling ambitions, and local reporting cites targets to ramp production materially in the coming year. At the same time, technical reliability, battery life, actuator durability and operational maintenance in contested environments remain critical risk factors that will shape procurement decisions.

On the strategic and regulatory front, the emergence of combat‑capable humanoid systems has intensified ethical and legal debates. International bodies and human‑rights organizations have called for clear limits on lethal autonomous weapons, while U.S. defense entities continue to explore autonomy under human oversight. Foundation’s field tests in Ukraine and discussions with U.S. agencies illustrate the faster feedback loop between real‑world trials and product development in this sector.

Market and policy analysts say the near‑term outlook hinges on demonstrable field performance and the evolution of procurement policies: if Phantom units validate non‑lethal logistics and reconnaissance roles reliably, defense buyers may accelerate contracts; if regulatory constraints tighten or technical setbacks occur, program timelines and valuations could be materially affected. Company statements suggesting validation this year and scale next year set expectations, but execution risk and governance questions will drive investor and buyer caution.